This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL
-
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234
City of Hope, Duarte, California, United States, 91010
H. Lee Moffitt Cancer Center, Tampa, Florida, United States, 33612
Winship Cancer Institute Emory University, Atlanta, Georgia, United States, 30322
Northside Hospital Cancer Institute, Atlanta, Georgia, United States, 30342
University of Maryland, Baltimore, Maryland, United States, 21201
Tufts Medical Center, Boston, Massachusetts, United States, 02111
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit, Michigan, United States, 48201
University of Minnesota, Minneapolis, Minnesota, United States, 55455
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Imugene Limited,
John Byon, MD, PhD, STUDY_CHAIR, Imugene Limited
2027-06